Monoclonal Antibody Combinations that Present Synergistic Neutralizing Activity: A Platform for Next-Generation Anti-Toxin Drugs

Monoclonal antibodies (MAbs) are among the fastest-growing therapeutics and are being developed for a broad range of indications, including the neutralization of toxins, bacteria and viruses. Nevertheless, MAbs potency is still relatively low when compared to conventional polyclonal Ab preparations....

Descripción completa

Detalles Bibliográficos
Autores principales: Diamant, Eran, Torgeman, Amram, Ozeri, Eyal, Zichel, Ran
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2015
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4488679/
https://www.ncbi.nlm.nih.gov/pubmed/26035486
http://dx.doi.org/10.3390/toxins7061854

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4488679/
https://www.ncbi.nlm.nih.gov/pubmed/26035486
http://dx.doi.org/10.3390/toxins7061854

Ejemplares similares